Company

Oyster Point Pharma, Inc.

Oyster Point Pharma is a Princeton, US biopharmaceutical company developing treatments for dry eye disease.

About

Founded in 2015 and headquartered in Princeton, US, Oyster Point Pharma focuses on ocular therapies, with TYRVAYA as its flagship product for dry eye. The company held an IPO in October 2019, raising USD 30 mn by selling 5 million shares at USD 16 each. In November 2022, Viatris Inc. agreed to acquire all outstanding shares at USD 11 per share.

2Funding rounds

6Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in